



**LUGPA**

Integrated Practices  
Comprehensive Care

# LUGPA 2025

# GLOBAL PROSTATE CANCER CONGRESS

IN PARTNERSHIP WITH



Specialty Networks™

*A Cardinal Health company*

**JANUARY 18 – 21, 2025**

Sun Valley Resort | Sun Valley, Idaho

lugpa.org    

# LUGPA 2025 GLOBAL PROSTATE CANCER CONGRESS



**LUGPA**  
Integrated Practices  
Comprehensive Care

**JANUARY 18 - 21, 2025**  
SUN VALLEY RESORT  
SUN VALLEY, IDAHO



**IN PARTNERSHIP WITH**

 **Specialty Networks™**  
A Cardinal Health company

LUGPA 2025 GLOBAL PROSTATE CANCER CONGRESS

## TABLE OF CONTENTS

- 3 Welcome Letter**
- 5 Educational Needs/Educational Objectives**
- 6 Accreditation and Designation Statements and Disclosure Report**
- 9 Program Agenda**
- 17 List of Speakers**
- 18 Faculty Biographies**
- 25 Thank You - Exhibitors**
- 26 Exhibit Hall Floor Plan**
- 27 Upcoming LUGPA Events**



# WELCOME



On behalf of the LUGPA Board of Directors, welcome to the Inaugural Global Prostate Cancer Congress at the beautiful and historic Sun Valley Resort in Sun Valley, Idaho. We have assembled an incredibly talented and world-renowned faculty who will take us from prostate cancer screening all the way to the most advanced stages of this challenging disease. Care was taken to highlight the hottest topics and provide state-of-the-art practical guidance in this exciting and rapidly changing space.

The program schedule is designed to get the most out of this three-day meeting. Educational sessions will start early in the morning and resume later in the afternoon, providing 9.5 hours of CME credit while allowing ample time to enjoy winter activities, midday. In addition, there are several industry-sponsored meal symposia and social events scattered throughout the program, and I encourage you to join us and support our industry partners. Without their dedication and commitment, meetings like this would not be possible. These meals and social activities are also great opportunities to network with your colleagues in a relaxed and fun environment.

I am very grateful to our leadership team for assembling this first ever event with such amazing results. A huge thank you to our program director, Dr. David Crawford, who has decades of experience as a prostate cancer thought leader and a meeting planner. I also wish to thank Dr. David Morris, who assisted me as a co-director, along with the entire LUGPA staff. With any brand-new event, the first go around is always the most difficult. This team, along with our colleagues from Specialty Networks, stepped up and did a phenomenal job.

Thank you for being part of history and attending the Global Prostate Cancer Congress 2025! We hope to make this an annual event and look forward to seeing you at future LUGPA meetings.

Sincerely,

**Scott B. Sellinger, MD**



## Officers

---

### President

Scott B. Sellinger, MD  
Tallahassee, FL

### President-Elect

Jeffrey Spier, MD  
El Paso, TX

### Secretary

Benjamin Lowentritt, MD, FACS  
Owings Mills, MD

### Treasurer

Kirsten Anderson, CMPE,  
CPC, CASC  
Myrtle Beach, SC

### Past President

Evan Goldfischer, MD  
Poughkeepsie, NY

## Board of Directors

---

Gordon Brown, DO, FACOS  
Sewell, NJ

Benjamin Coons, MD  
Colorado Springs, CO

Nathan Diller, MBA, MHSA,  
FACHE, CMPE  
Wilmington, DE

Erika Ferrozio, MHA  
Meridian, ID

Jason Hafron, MD  
Troy, MI

Vahan Kassabian, MD, FACS,  
FRCS (C)  
Atlanta, GA

David Morris, MD  
Nashville, TN

Timothy Richardson, MD  
Wichita, KS

## Chief Executive Officer

---

Celeste G. Kirschner, CAE

875 N. Michigan Avenue  
Suite 3100  
Chicago, IL 60611  
[www.lugpa.org](http://www.lugpa.org)



# LUGPA FEATURED PROGRAMS AND PRODUCTS

## LUGPA's Benchmarking Program How does your practice measure up?



Not a member of LUGPA's Benchmarking program? It's not too late to join. For those who participate in the program, InfoDive®, IQSS' business analytics solution, provides a HIPAA-compliant secure data exchange from various practice management systems to benchmark productivity, financial, and coding metrics for practice, provider, and patient-level data. These insights will allow for strategic reporting of urology-specific benchmarks and help your practice identify potential opportunities for performance improvement and risk mitigation.

These benchmarking metrics will also assist LUGPA in providing educational and research programs as well as provide analytical support to key LUGPA health policy initiatives.

**With InfoDive, you gain more than just benchmarking insights. As a participating practice, you gain valuable insight into practice performance that will allow you to:**

- Analyze key financial metrics that can help with payer negotiations
- Compare coding patterns to help mitigate audit risk
- Evaluate net cost recovery based on adjudicated claims, invoice cost, and rebates through InfoDive's Buy and Bill report
- Uncover inaccurate or missed drug billing opportunities, revenue leakage, and compliance issues with InfoDive's GapFinder®
- Access robust profiling of new patients, referrals, and patient demographics to target marketing efforts
- Monitor your fee schedule to identify underpriced services
- Access urology-specific reports including Stent Removal Tracking, Prostate Biopsy Analysis, Prostate Cancer Analysis, Stone Treatment Profile, and American Board of Urology Report

For more information on the benchmarking program and how to join, please contact **Kathy Stack** at [kstack@lugpa.org](mailto:kstack@lugpa.org) or **312.728.0137**. If you are not a current InfoDive user and would like more information or a product demonstration, please contact [info@intrinsiq.com](mailto:info@intrinsiq.com).

## EDUCATIONAL NEEDS

The urologist, in working with oncologists and radiation oncologists as a team to diagnose and treat prostate cancer has been developing as evidenced by the multitude of FDA approved diagnostic, imaging and therapeutics. Urologists, oncologists and radiation oncologists are challenged with keeping up-to-date with research findings and participating in studies that will enhance care for prostate cancer patients.

Challenges involve providing ongoing education to address not only the most recently presented/ published trial data of these above-mentioned advances and innovations but also how to best operationalize, understand and optimize diagnosis, reduce complications, evaluate therapeutic selection and ongoing management of the patient. Thus, the course will address these issues specifically focusing on elements to precisely diagnose and treat prostate cancer and change current practice patterns that will lead to better patient outcome.

---

## EDUCATIONAL OBJECTIVES

**At the conclusion of the LUGPA 2025 CME Program, attendees will be able to:**

1. Describe the biological mechanisms and genetic factors involved in the development and progression of prostate cancer.
2. Evaluate the current screening methods for prostate cancer, such as PSA testing and digital rectal exams, and understand their benefits and limitations.
3. Describe the various diagnostic approaches, including imaging modalities (MRI, CT, PET scans) and biopsy techniques, as well as staging criteria for prostate cancer.
4. Compare and contrast the various treatment options for localized and advanced prostate cancer, including surgery, radiation therapy, hormone therapy, chemotherapy, and emerging treatments.
5. Develop strategies for managing the side effects and complications of prostate cancer treatments, including urinary incontinence, sexual dysfunction, and metabolic changes.
6. Explore the latest research findings and future directions in prostate cancer, including advancements in genetic testing, immunotherapy, and personalized medicine.
7. Review and appraise resources about legislation related to prostate cancer.

# ACCREDITATION AND DESIGNATION STATEMENTS AND DISCLOSURE REPORT

## Global Prostate Cancer Congress

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the LUPGA. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the live format for this educational activity for a maximum of *9.5 hours AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activities.

*The live approval period is: January 18-21, 2025.*

# ACCREDITATION AND DESIGNATION STATEMENTS AND DISCLOSURE REPORT

## Financial Disclosures.

The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

FULL LEGAL NAME	COMMERCIAL INTEREST	ROLE	Level of participation in the activity
David Albala	Applied Medical Bio-Techne, Lantheus	Stock/Consultant Speaker	Speaker
E. David Crawford	UroToday	Editor	Speaker
Jason Efstathiou	Blue Earth Diagnostics Clarity Pharmaceuticals Clarity Pharmaceuticals UpToDate Angiodynamics, Myovant Sciences Pfizer/Astellas, Lantheus/ Progenics Pharmaceuticals, Boston Scientific Elekta, IBA	Consultant, Advisory Board Honoraria  Advisory Board  Consultant Honoraria, Speaker	Speaker
Evan Goldfischer	Johnson & Johnson, Pfizer, Lantheus, Bayer	Speaker, Consultant	Speaker
Jonathan Henderson	AstraZeneca, Photocure, Verity, Myovant JNJ	Advisor, Speaker	Speaker
Maha Hussain	Bayer, Tango, Novartis AZ, Bayer	Advisory Board Honorarium	Speaker
Amir Iravani	Novartis, Lantheus, Curium, Bayer Ambrx	Advisor Consultant (through institution)	Speaker
Laurence Klotz	miR Scientific Profound Inc., Exact Imaging	Consultant Research Support	Speaker
Phillip Koo	Johnson and Johnson, Blue Earth, Bayer, Novartis, AstraZeneca, ConcertAI, Pfizer, Lantheus, Astellas Cardinal Health	Consulting Education	Speaker
Arturo Mendoza-Valdes	Janssen, Bayer, AstraZeneca, Teva Pfizer	Speaker Advisor	Speaker
Martin Miner	Halozyne, Tolmar	Advisor	Speaker
Todd Morgan	ClevelandDx, Foundation Medicine	Advisory Board	Speaker

# ACCREDITATION AND DESIGNATION STATEMENTS AND DISCLOSURE REPORT

## Financial Disclosures.

The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:

*"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."*

FULL LEGAL NAME	COMMERCIAL INTEREST	ROLE	Level of participation in the activity
David Morris	Johnson & Johnson, Bayer, Astellas Cleveland Diagnostics, Decipher Bio, Tomar, Myovant, Blue Earth, Dendreon, Progenics, Lantheus AstraZeneca Merck Pfizer	Consulting, Advisory, Research  Consulting Consulting, Research Speaking, Research Consulting, Advisory	Speaker
J. Curtis Nikel	Inmunotek, Redleaf Medical OM Pharma MicroGenDx	Research, Consultant Consultant Researcher	Speaker
Peter Orio	Teleflex, Inc., Theragenics Corp.	Consultant	Speaker
Rutveej Patel	Integra LifeSciences	Speaker	Speaker
Thomas Polascik	Merck, Astellas, Ferring, Janssen	Research	Speaker
Robert Reiter	Bayer, Johnson and Johnson Pfizer, Lantheus	Speaker Consultant	Speaker
Scott Sellinger	Foundation Medicine, Pfizer, Astellas, MDX Health, Tempus, AstraZeneca, Accord Bio, Lantheus, Bayer	Speaker/Consultant	Speaker/Planner - Reviewer
Paul Sieber	Sumitomo, CG Oncology, ORIC Accord Biopharma Bayer, Janssen, Dendreon, Astellas, Merck, Pfizer	Researcher Speakers Bureau  Speakers Bureau, Researcher	Speaker

These financial relationship(s) with ineligible companies have been mitigated by PeerPoint Medical Education Institute and the LUGPA.

All other presenters, planners, editors, or staff report no relationships to disclose:

*"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."*



# AGENDA

## Saturday, January 18, 2025

*\*Topics and Speakers Subject to Change*



TIME	SESSION TITLE	LOCATION
5:00 p.m. – 7:00 p.m.	<b>Meeting Registration/Information</b>	Limelight B Promenade
6:00 p.m. – 7:00 p.m.	<b>Networking Reception in the Exhibit Hall</b>	Continental Room

## Sunday, January 19, 2025

*\*Topics and Speakers Subject to Change*

TIME	SESSION TITLE	LOCATION
6:15 a.m. – 10:30 a.m. 3:30 p.m. – 6:30 p.m.	<b>Meeting Registration/Information</b>	Limelight B Promenade
6:45 a.m. – 7:00 a.m.	<b>Welcome and Introductory Remarks</b> E. David Crawford, MD and Scott Sellinger, MD	Limelight A & B
7:00 a.m. – 8:15 a.m.	<p><b>Session 1: Men's Health Issues</b> Moderator: Martin Miner, MD</p> <p>7:00 a.m. – 7:10 a.m. <b>State of Art: Male Mortality</b> Martin Miner, MD</p> <p>7:10 a.m. – 7:20 a.m. <b>Cardio-Oncology ADT</b> David Morris, MD</p> <p>7:20 a.m. – 7:30 a.m. <b>Caretaker Burnout</b> Reena Cherry, PA-C</p> <p>7:30 a.m. – 7:40 a.m. <b>Noncardiac Side Effects of ADT</b> Scott B. Sellinger, MD</p> <p>7:40 a.m. – 8:15 a.m. <b>Panel Discussion/Patient Perspective/Q &amp; A</b> Moderators: Scott B. Sellinger MD &amp; Martin Miner, MD</p> <p><b>Session 1 Selected Abstract</b> 1) Celestia (Tia) S. Higano, MD, FACP -Prostate Cancer Supportive Care (PCSC) Program: A Model For Meeting An Unmet Need For PC Patients.</p>	

**Sunday, January 19, 2025***\*Topics and Speakers Subject to Change*

TIME	SESSION TITLE	LOCATION
8:15 a.m. – 9:00 a.m.	<b>Industry Sponsored Breakfast Symposium</b> <b>Evidence-Based, Practical Strategies for Providing Comprehensive Care to Men on Androgen Deprivation Therapy</b> E. David Crawford, MD  Sponsored by: 	Limelight C
9:00 a.m. – 10:30 a.m.	<b>Session 2: Risk Stratified Approach to diagnosing Prostate Cancer</b> Moderator: Michael Liss, MD, PhD, MAS, FACS  9:15 a.m. – 9:25 a.m. <b>State of the Art:</b> <b>Prostate Cancer Risk Stratification: The Synergy of PSA, Biomarkers and MRI</b> Robert Reiter, MD  9:25 a.m. – 9:35 a.m. <b>Urinary Microbiome and its Impact</b> Michael Liss, MD, PhD, MAS, FACS  9:35 a.m. – 9:45 a.m. <b>Prostate Cancer Screening, Tools, Techniques and Advanced Biomarkers</b> William Parker, MD  9:45 a.m. – 9:55 a.m. <b>Website Approach for Prostate Cancer Markers</b> E. David Crawford, MD  9:55 a.m. – 10:05 a.m. <b>Markers: Radiation and ADT</b> Jason Efstathiou, MD, DPhil  10:05 a.m. -10:40 a.m. <b>Panel Discussion and Challenging Cases</b> Moderator: Michael Liss, MD, PhD, MAS, FACS  <b>Session 2 Selected Abstracts</b> 1) Prisca Mbonu, MD-Trends in Genetic Counseling Referrals and Testing for Prostate Cancer in a Large Safety-Net Hospital.	Limelight A & B
10:40 a.m. – 3:30 p.m.	<b>Free Time</b>	
3:30 p.m. – 4:15 p.m.	<b>Industry Sponsored Mid-Day Symposium</b> <b>Treatment of mCRPC: Results From Key Clinical Trials</b> Scott B. Sellinger, MD  Sponsored by: 	Limelight C


## Sunday, January 19, 2025

*\*Topics and Speakers Subject to Change*

TIME	SESSION TITLE	LOCATION
4:15 p.m. – 5:25 p.m.	<p><b>Session 3: Role of Genomics and Genetics in Prostate Cancer</b> Moderators: David Morris, MD and Todd Morgan, MD</p> <p>4:15 p.m. – 4:25 p.m. <b>Newly Identified Mutations Associated with Prostate Cancer Risk and Aggressiveness</b> Brian Helfand, MD, PhD</p> <p>4:25 p.m. – 4:35 p.m. <b>Predictive Markers for Radiation Oncology</b> Peter Orio III, DO, MS</p> <p>4:35 p.m. – 4:45 p.m. <b>Radiogenomics and Natural History of MR Visible vs. Invisible Prostate Cancer: Clinical Implications</b> Laurence Klotz, MD, FRCSC</p> <p>4:45 p.m. – 4:55 p.m. <b>Microbiome and Prostate Cancer</b> Michael Liss, MD, PhD, MS</p> <p>4:55 p.m. – 5:25 p.m. <b>Panel Discussion and Q &amp; A</b> Moderators: David Morris, MD and Todd Morgan, MD</p> <p><b>Session 3 Selected Abstracts</b></p> <p>1) Kshitij Pandit, MD - Evaluation of Urinary Prostate Cancer Biomarkers in Predicting Biopsy Outcomes.</p> <p>2) Aaron Milbank, MD - IsoPSA Large Scale Prospective Validation Study: - In Patients without Multi-Parametric MRI. In Patients with Abnormal DRE.</p>	Limelight A & B
5:25 p.m. – 6:00 p.m.	<b>Exhibit Hall</b>	Continental Room
6:00 p.m. – 6:45 p.m.	<p><b>Session 4: Health Policy and Political Advocacy</b> Moderator: Scott B. Sellinger, MD, FACS Panel: Evan Goldfischer, MD, Mara Holton, MD, David Albala, MD, Richard Harris, MD and Jonathan Henderson, MD</p>	Limelight A & B
6:45 p.m. – 6:50 p.m.	<p><b>Conclusion and Highlights of the Next Day</b> E. David Crawford, MD and Scott Sellinger, MD, FACS</p>	
6:50 p.m. – 8:45 p.m.	<p><b>Social Activity – Bowling</b> (with food and beverages)</p>	Sun Valley Lodge Bowling Alley

## Monday, January 20, 2025

*\*Topics and Speakers Subject to Change*

TIME	SESSION TITLE	LOCATION
6:30 a.m. – 10:30 a.m. 3:30 p.m. – 6:45 p.m.	<b>Meeting Registration/Information</b>	Limelight B Promenade
7:00 a.m. – 8:00 a.m.	<p><b>Session 5: Molecular Targeted Imaging</b> Moderator: Phillip Koo, MD</p> <p>7:00 a.m. – 7:10 a.m. <b>Predictive Value of PSMA PET in Prostate Cancer</b> Amir Iravani, MD</p> <p>7:10 a.m. – 7:20 a.m. <b>MTI in Patient Selection and Monitoring of Patients Undergoing Radioligand Therapy</b> Phillip Koo, MD</p> <p>7:20 a.m. – 7:30 a.m. <b>Value of Integration of PSMA PET into a Urology Practice</b> David Albala, MD</p> <p>7:30 a.m. – 7:40 a.m. <b>High Resolution Micro Ultrasound: Complementary to MRI, or a Replacement for MRI</b> Laurence Klotz, MD, FRCSC</p> <p>7:40 a.m. – 8:00 a.m. <b>Panel Discussion/ Q &amp; A</b> Moderator: Phillip Koo, MD</p> <p><b>Session 5 Selected Abstract</b> 1) Sakina Mohammad Mota, PhD Risk Assessment and Localization Using an AI Prostate Cancer Mapping Algorithm</p>	Limelight A & B
8:00 a.m. – 8:45 a.m.	<p><b>Industry Sponsored Breakfast Symposium</b> <b>Radioligand Therapy (RLT) Logistics, Administration &amp; Radiation Therapy</b> Tom Boike, MD, MMM, FASTRO</p> <p>Sponsored by:  <b>NOVARTIS</b></p>	Limelight C
8:45 a.m. – 9:15 a.m.	<b>Exhibit Hall</b>	

## Monday, January 20, 2025

*\*Topics and Speakers Subject to Change*

TIME	SESSION TITLE	LOCATION
9:15 a.m. – 10:15 a.m.	<p><b>Session 6: Localized Prostate Cancer</b> Moderator: Peter Orio, III, DO, MS</p> <p>9:15 a.m. – 9:25 a.m. <b>Novel Focal Treatments for Prostate Cancer</b> Thomas Polascik, MD</p> <p>9:25 a.m. – 9:35 a.m. <b>The Role of Radiation Oncology</b> Peter Orio III, DO, MS</p> <p>9:35 a.m. – 9:45 a.m. <b>A Trial of Protons vs IMRT for Local Therapy</b> Jason Efstathiou, MD, DPhil</p> <p>9:45 a.m. – 9:55 a.m. <b>Navigating Treatment Choices: Active Surveillance vs. Focal vs. Radical Treatment for intermediate risk prostate cancer</b> Brian Helfand, MD, PhD</p> <p>9:55 a.m. – 10:15 a.m. <b>Panel Discussion/Q &amp; A</b> Moderator: Peter Orio, III, DO, MS</p> <p><b>Session 6 Selected Abstract</b> 1) Gerald Andriole, MD -Comparing Prostatype P-score and Traditional Risk Models in Predicting Prostate Cancer Outcomes in Spain</p>	Limelight A & B
10:15 a.m. – 3:30 p.m.	<b>Free Time</b>	
3:30 p.m. – 4:30 p.m.	<p><b>Industry Sponsored Mid-Day Symposium</b> <b>Getting Ahead of Advanced Prostate Cancer</b> David Morris, MD</p> <p>Sponsored by: <b>Johnson&amp;Johnson</b></p>	Limelight C





## Monday, January 20, 2025

*\*Topics and Speakers Subject to Change*

TIME	SESSION TITLE	LOCATION
4:30 p.m. – 5:30 p.m.	<p><b>Session 7: Advanced Prostate Cancer</b> Moderator: Scott B. Sellinger, MD, FACS</p> <p>4:30 p.m. – 4:45 p.m. <b>State of the Art: mHSPC, mCRPC, Roles of PARP-I</b> Maha Hussain, MD, FASCO</p> <p>4:45 p.m. – 4:55 p.m. <b>Using Germline Genetics to Identify Men at Risk of Side Effects from ADT</b> Brian Helfand, MD, PhD</p> <p>4:55 p.m. – 5:05 p.m. <b>Management of Non-Metastatic Biochemical Recurrence After Radiation</b> William Parker, MD</p> <p>5:05 p.m. – 5:30 p.m. <b>Panel Discussion/Q &amp; A</b> Moderator: Scott B. Sellinger, MD, FASC</p> <p><b>Session 7 Selected Abstract</b></p> <p>1) David Morris, MD - Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer from the Phase 3 Aranote Trial</p> <p>2) Sabree Burbage - Overall Survival in Patients with Metastatic Castration Sensitive Prostate Cancer Treated With Apalutamide versus Abiraterone Acetate – A Head-to-Head Analysis of Real-World Patients in the United States</p>	Limelight A & B
5:20 p.m. – 6:00 p.m.	<b>Exhibit Hall</b>	Continental Room
6:00 p.m. – 6:40 p.m.	<p><b>Session 8: Industry: Rapid Fire</b></p> <p>Sabree Burbage - Real-World Head-to-Head Analysis of Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide versus Enzalutamide in the United States</p>	Limelight A & B
7:00 p.m. – 9:30 p.m.	<p><b>LUGPA and Specialty Network’s Dinner Fire Side Chat:</b></p> <p>E. David Crawford, MD, J Curtis Nickel, MD, Reena Cherry, PA-C and Tim Coughlin</p>	Limelight C

## Tuesday, January 21, 2025

*\*Topics and Speakers Subject to Change*

TIME	SESSION TITLE	LOCATION
6:30 a.m. – 10:30 a.m.	<b>Meeting Registration/Information</b>	Limelight B Promenade
7:00 a.m. – 8:00 a.m.	<p><b>Session 9: Advanced Prostate Cancer</b> Moderator: Dan Petrylak, MD</p> <p>7:00 a.m. – 7:10 a.m. <b>State of Art: mCRPC – Inroads and Improved Outcomes</b> Dan Petrylak, MD</p> <p>7:10 a.m. – 7:20 a.m. <b>Bone Health</b> Paul Sieber, MD</p> <p>7:20 a.m. – 7:30 a.m. <b>Lessons Learned</b> J. Curtis Nickel, MD, FRCSC</p> <p>7:30 a.m. – 8:30 a.m. <b>Panel Discussion/ Q &amp; A</b> Moderator: Dan Petrylak, MD</p> <p><b>Session 9 Selected Abstract</b> 1) Neal Shore, MD Patient Characteristics, Treatment Patterns, and Early Trends of Lutetium Lu 177 Vipivotide Tetraxetan Use by US Urologists and Oncologists</p>	Limelight A & B
8:00 a.m. – 8:45 a.m.	<p><b>Industry Sponsored Breakfast Symposium</b> <b>Treatment Intensification with XTANDI (Enzalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cancer &amp; Nonmetastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence at High Risk for Metastasis</b> Vahan Kassabian, MD, FACS, FRCS</p> <p>Sponsored by:  </p>	Limelight C

## Tuesday, January 21, 2025

*\*Topics and Speakers Subject to Change*

TIME	SESSION TITLE	LOCATION
8:45 a.m. – 9:45 a.m.	<p><b>Session 10: Preventing and treating side effects</b> Moderator: E. David Crawford, MD</p> <p>8:45 a.m. – 8:55 a.m. <b>Exercise as Part of the Prevention and Treatment of Side Effects</b> Arturo Mendoza- Valdés, MD</p> <p>8:55 a.m. – 9:05 a.m. <b>ADT and ARPIs: Minimizing Side Effects and Maximizing Benefit</b> Laurence Klotz, MD, FRCSC</p> <p>9:05 a.m. – 9:15 a.m. <b>Prevalence and Treatment Options for ED and MC Post Prostatectomy and Value and Efficiency of having a PA Integrated into the Pathway</b> Rutveej Patel, MD</p> <p>9:15 a.m. – 9:45 a.m. <b>Panel Discussion/Q &amp; A</b> E. David Crawford, MD</p>	Limelight A & B
9:45 a.m. – 10:30 a.m.	<p><b>Late Breaking Presentations and Abstracts</b></p> <ol style="list-style-type: none"> <li>1) Ned Ruhotina, MD - AI Enabled Clinical Trial Screening Platform.</li> <li>2) Christopher Lee, MD- Genomic, Germline, and Somatic Tumor Testing: a Descriptive Analysis of Patients with Prostate Cancer in an open-Access Collaborative Research Registry.</li> <li>3) Bob Yang- Post-prostatectomy Application of the Pacey Cuff.</li> <li>4) Aaron Milbank, MD IsoPSA Large Scale Prospective Validation Study: Performance of the IsoPSA Test in Patients with No Prior Biopsy</li> </ol> <p><b>Conclusion/Closing Remarks/Adjourn</b></p>	

# LIST OF SPEAKERS

## PROGRAM CHAIR

### **E. David Crawford, MD**

Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus  
*Denver, CO*

## CO-CHAIR

### **Scott Sellinger, MD, FACS**

Partner, Advanced Urology Institute  
*Tallahassee, FL*

## CO-CHAIR

### **David Morris, MD**

President and the Co-Director for the Advanced Therapeutics Center at Urology Associates  
*Nashville, TN*

## INVITED FACULTY

### **David Albala, MD**

Chief of Urology at Crouse Hospital and a member of Associated Medical Professionals  
*Syracuse, NY*

### **Reena Cherry, PA-C**

Physician Assistant, UC San Diego Health  
*San Diego, CA*

### **Tim Coughlin**

President of DMG Financial  
*Denver, CO*

### **Jason Efstathiou, MD, DPhil, FASTRO, FACRO**

Professor of Radiation Oncology at Harvard Medical School  
*Boston, MA*

### **Evan Goldfischer, MD**

CEO, Premier Medical Group of Hudson Valley PC  
*Poughkeepsie, NY*

### **Richard Harris, MD**

CEO and President of UroPartners  
*Chicago, IL*

### **Brian Helfand, MD, PhD**

Richard Melman and Ron Chez Family Chair and Chief of the Division of Urology at Endeavor Health  
*Evanston, IL*

### **Jonathan Henderson, MD**

Urologist, Arkansas Urology  
*Little Rock, AR*

### **Mara Holton, MD**

Founder and Director, Women's Wellness Center at Anne Arundel Urology  
*Annapolis, MD*

### **Maha Hussain, MD, FACP, FASCO**

Genevieve Teuton Professor of Medicine in the Division of Hematology-Oncology, Department of Medicine, and the Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine  
*Chicago, IL*

### **Amir Iravani, MD**

Associate Professor of Radiology at the Department of Radiology, University of Washington School of Medicine and Theragnostic Director at Fred Hutchinson Cancer Center  
*Seattle, WA*

### **Laurence Klotz, MD, FRCSC**

Professor of Surgery and Sunnybrook Chair of Prostate Cancer Research at University of Toronto  
*Toronto, Ontario, Canada*

### **Phillip Koo, MD**

Chief of Diagnostic Imaging and Physician Executive of Oncology at the Banner MD Anderson Cancer Center,  
*Phoenix, AZ*

### **Michael Liss, MD, PhD, MAS, FACS**

Urologic oncologist, UT Health MD Anderson Center  
*San Antonio, TX*

### **Arturo Mendoza-Valdés, MD**

Professor in the Urology Residency Program at INNSZ  
*Mexico City, Mexico*

### **Martin, Miner, MD**

Professor of Family Medicine and Urology, Brown University  
*Providence, RI*

### **Todd Morgan, MD**

Jack Lapides, M.D. Research Professor, Chief of Urologic Oncology and Co-Director of the Weiser Center for Prostate Cancer at the University of Michigan  
*Ann Arbor, MI*

### **J. Curtis Nickel, MD, FRCSC**

Professor Emeritus, Department of Urology, Queen's University and Kingston Health Sciences Centre  
*Kingston, Ontario, Canada*

### **Peter Orio, III, DO, MS**

Vice Chair of Network Operations Director of Prostate Brachytherapy Department of Radiation Oncology Dana-Farber | Brigham Cancer Center Professor, Harvard Medical School  
*Boston, MS*

### **William Parker, MD**

Urologist at The University of Kansas Health System and Associate Professor at the University of Kansas Medical Center  
*Kansas City, KS*

### **Rutveej Patel, MD**

Urologic Oncologist, Advanced Urology Institute of Georgia, PC  
*Snellville, GA*

### **Daniel P. Petrylak, MD**

Professor of Medicine Medical Oncology) and Urology Yale School of Medicine  
*New Haven, CT*

### **Thomas J. Polascik, MD**

Surgical Oncologist, Urologic Oncologist Duke Health  
*Durham, NC*

### **Robert Reiter, MD, MBA**

Bing Professor of Urologic Oncology, Chief of the Division of Urologic Oncology, and Director of UCLA's Prostate Cancer Program University of California Los Angeles  
*Los Angeles, CA*

### **Paul Sieber, MD**

Medical Director for Clinical Trials Keystone Urology  
*Lancaster, PA*

## FACULTY BIOGRAPHIES

**David M. Albala, MD**

Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr. Albala was an endourology fellow at Washington University Medical Center under the direction of Ralph V. Clayman. He practiced at Loyola University Medical Center in Chicago and rose from the ranks of Instructor to full Professor in Urology and Radiology in eight years. Ten years later, he became a tenured Professor at Duke University Medical Center in North Carolina. At Duke, he was Co-Director of the Endourology fellowship and Director for the Center of Minimally Invasive and Robotic Urological Surgery. He has over 247 publications in peer-reviewed journals and has authored three textbooks in endourology and seven in general urology. He is the Editor-in-Chief of the Journal of Robotic Surgery. He serves on the editorial board for Medical Reviews in Urology, Current Opinions in Urology and Urology Index and Reviews. He serves as a reviewer for eight surgical journals. He is a Visiting Professor in the Department of Urology at SUNY Downstate Health Sciences University. In addition, he was ranked among the top 2% of urologists in the world by a Stanford University study done in May 2021.

At the present time he is Chief of Urology at Crouse Hospital and a member of Associated Medical Professionals in Syracuse, New York. He is considered a national and international authority in laparoscopic and robotic urological surgery and has been an active teacher in this area for over 20 years. His research and clinical interests have focused on robotic urological surgery. In addition, other clinical interests include minimally invasive treatment of benign prostatic hypertrophy (BPH), biomarkers in prostate cancer, and the use of fibrin sealants in surgery. He has been a Visiting Professor

at numerous institutions across the United States as well as overseas in countries such as India, China, Iceland, Germany, France, Japan, Brazil, Australia, and Singapore. In addition, he has done operative demonstrations in over 32 countries and 23 states. He has trained 19 fellows in endourology and advanced robotic surgery.

In addition, Dr. Albala is a past White House Fellow who acted as a special assistant to Federico Pena, Secretary of Transportation, on classified and unclassified public health-related issues.

**Reena Cherry, PA-C**

Reena Cherry is a highly accomplished board-certified surgical and medical oncology Physician Assistant with a distinguished career spanning 24 years in the oncology space. Throughout this time, Reena has served patients as an expert clinician at two of the nation's most prestigious healthcare institutions: MD Anderson Cancer Center and UC San Diego Health.

Reena brings a wealth of experience to the field of oncology, specializing in prostate cancer, bladder cancer, kidney cancer, and testicular cancer. With a deep commitment to compassionate patient care, Reena also dedicates her time to supporting the needs of formal and informal caregivers who are, in many ways, the backbone of our healthcare system.

Reena received her bachelor of science degree in Psychology from Spelman College in Atlanta, Georgia and her master of science degree in Physician Assistant studies at Baylor College of Medicine in Houston, Texas. Reena is a member of the American Association of Physician Assistants (AAPA), the Association for Physician Assistants in Oncology (APAO), the California Association of Physician Assistants (CAPA), and the Schwartz Center for Compassionate Healthcare. Additionally, Reena holds board appointments on the Prostate

Conditions Education Council, the Jack A. Vickers Scientific Advisory Board, and the Kidney Cancer Association Clinical Advisory Board.

**Timothy E. Coughlin**

Timothy E. Coughlin is the President of DMG Financial, a nationally recognized consulting firm specializing in the beverage distribution industry located in Denver, CO. Mr. Coughlin has performed multiple valuations and assisted many beer distributors and their advisors with acquisitions, divestitures, mergers, and other matters. Mr. Coughlin joined DMG Financial in 1998. Prior to DMG Financial, Mr. Coughlin provided financial and litigation consulting services to attorneys and their clients including liability assessments, damage calculations, loss calculations, and damage analyses for various legal matters including personal injury and wrongful death lawsuits, breach of contract, and labor disputes Mr. Coughlin has a Bachelor of Science in Business and Organizational Management from the University of Colorado, Boulder. He is also a member of the National Beer Wholesalers Association.

**Dr. E. David Crawford**

Dr. Crawford is the distinguished Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus. He is an active clinician, researcher, and teacher. He has been recognized as one of the Best Doctors in America, one of the Best Cancer Doctors, one of the Top 20 Urologists in the county by Men's Health Magazine, and recently selected as the Healthcare Provider of the Year in the Denver Metro Area by The Denver Business Journal.

In addition, he is the recipient of more than 95 research grants in the diagnosis and treatment of prostate cancer, metastatic prostate cancer, hormone refractory prostate cancer, benign prostatic hyperplasia (BPH), advanced bladder cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 600 published articles, contributed to nearly 100 educational books and provided thousands of educational talks for patients and physicians.

In an effort to raise awareness and education about prostate health, Dr. Crawford founded and is the current Chairman of the Prostate Conditions Education Council, a non-profit organization which is responsible for reaching an average of 400 million people each year with education and awareness information.

On prostate cancer and men's health issues, his involvement in the national prostate cancer arena has been widely recognized and he is often requested to act as an educator, speaker, participate in advisory boards, review research or serve as a legal expert.

Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, American Urological Association (AUA), and the American Association for the Advancement of Science.

**Jason A. Efstathiou, MD, DPhil, FASTRO, FACRO**

Dr. Efstathiou is Professor of Radiation Oncology at Harvard Medical School (HMS), Vice-Chair for Faculty & Academic Affairs and Director of the Genitourinary (GU) Division in the Department of Radiation Oncology, and Clinical Co-Director of The Claire and John Bertucci Center for GU Cancers at the Massachusetts General Hospital/ Mass General Brigham.



He is an internationally recognized leader in the field of GU malignancies and Radiation Oncology. His research has informed clinical guidelines and made novel contributions to technology assessment of proton beam therapy for prostate cancer, organ preservation therapy for bladder cancer, as well as global oncology outreach efforts. He is the recipient of significant grant funding and serves as the Principal Investigator (PI) or Co-Chair of multiple multi-center, NCI-sponsored, randomized trials in prostate and bladder cancer, including PI of the PARTIQoL RCT of protons vs photons for localized prostate cancer. Dr. Efsthathiou holds multiple leadership and Board positions within professional societies (ASTRO, ASCO, ABR, ACRO, ROI) including serving as Past-Chair of the

Genitourinary Cancers Symposium (GU ASCO), within patient advocacy organizations (BCAN, MPCC), within the NCI where he previously served as Co-Chair of the Bladder Cancer Task Force and currently serves as Co-Chair of the GU Steering Committee, and within NRG Oncology where he is the Vice-Chair of the GU Steering Committee and Bladder Lead.

In addition, he has a strong proven track record in teaching and mentorship and was recently awarded the A. Clifford Barger Excellence in Mentoring Award from HMS. Dr. Efsthathiou holds a B.S. from Yale University, M.D. from HMS, D.Phil. from the University of Oxford, and completed his residency training in the Harvard Radiation Oncology Program.



**Evan P. Goldfischer, MD, MBA, CPI, MPH**

Dr. Goldfischer received his BA from Tufts University and his MD from Cornell University Medical College. He completed his internship in general surgery and his residency in urology at the University of Chicago. He completed a fellowship in endourology under the direction of Arthur Smith at Long Island Jewish

Medical Center. Dr. Goldfischer received his MBA from the University of Massachusetts and is a Certified Physician Executive. He served as the co-founding CEO of Premier Medical Group of the Hudson Valley, as well as founding Director of Research. Dr. Goldfischer has written over 100 peer-reviewed abstracts and publications and has lectured on six continents. In addition, he was elected to the LUGPA Board of Directors in 2014 currently serving as President. He is the Editor-in-Chief of Practice Management for Urology Groups: LUGPA's Guidebook Second Edition published in 2020 and is the author of Even Urologists Get Kidney Stones – A Guide to Prevention and Treatment, published in 2018.




**Richard Harris, MD**

Dr. Harris is a founding member and now the CEO and President of UroPartners, an integrated urology/pathology/radiation oncology practice with over 60 physicians. He has been in the private practice of urology in Chicago for the last 31 years and currently focuses on the treatment of prostate cancer, specifically metastatic castrate resistant prostate cancer.

Dr. Harris attended Washington University in St. Louis, and the Chicago Medical School. He completed his residency in general surgery and urology at Loyola University Medical Center.

Dr. Harris has been involved in pharmaceutical research and has performed over 100 clinical trials in drug development. He has served on LUGPA's Board of Directors for the last 10 years and is currently the Past President. Dr. Harris is also an assistant clinical professor of urology at Loyola University Medical Center.



**Brian Helfand, MD, PhD**

Dr. Helfand is the Richard Melman and Ron Chez Family Chair and Chief of the Division of Urology at Endeavor Health, formerly NorthShore University HealthSystem, in Evanston, Illinois. He is a Clinical Professor at the University of Chicago and former Adjunct Professor at Northwestern University. He holds a dual MD, PHD degrees and is head of a clinical and research programs focused on prostate cancer. Dr. Helfand has authored more than 250 peer reviewed manuscripts. He has been involved in many clinical trials evaluating surgical interventions (e.g. minimally invasive robotic techniques and focal therapies), biomarkers (e.g. genetics) and imaging technologies (PET imaging radiotracers) for men with early and late stage prostate cancer. Currently, his clinical and research interests are devoted towards using multiparametric testing to help improve prostate cancer decision making.



**Jonthan Henderson, MD**

Dr. Henderson earned a Bachelor of Science Degree at LSU in Baton Rouge in microbiology. After receiving his M.D. at LSU Medical Center in Shreveport, he completed his internship and residency in Urology at LSUMC Hospital.

Dr. Henderson spent the next six years in practice in Alabama where he pioneered urologic laparoscopy. In 2002, Dr. Henderson was asked to return to Shreveport to join the nascent Regional Urology and served as CEO. In March 2022 Dr. Henderson joined Arkansas Urology in Little Rock, Arkansas.

Dr. Henderson is certified by the American Board of Urology. He is a member of the American Urologic Association (and sits on many committees for that organization),

Shreveport Medical Society, Louisiana State Medical Society, and the Alpha Omega Alpha Medical Honor Society. He has been on the LUGPA Board of Directors since 2011 and is the Immediate Past President.



**Mara B. Holton, MD**

Dr. Mara Holton graduated from Temple University School of Medicine in 2001. She received her surgical and urology training at the University of Maryland Medical Center. She is certified by the American Board of Urology and is licensed in the state of Maryland. She is clinically focused on the care of women's urological and pelvic floor health and has served as the CEO of her group, Anne Arundel Urology, for the past 4 years. She is a Board member of LUGPA, a member of the American Urological Association and is the founder and director of the Women's Wellness Center at Anne Arundel Urology.



**Maha Hussain, MD, FACP, FASCO**

Dr. Hussain is the Genevieve Teuton Professor of Medicine in the Division of Hematology-Oncology, Department of Medicine, and the Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine. Dr. Hussain received her medical degree from Baghdad University College of Medicine and completed her residency and Hem-Onc fellowship at Wayne State University in Detroit, Michigan. She was a faculty at Wayne State University and worked at the Allen Park VA and Detroit VA for many years. Dr. Hussain is a practicing oncologist, internationally renowned expert and clinical researcher in genitourinary oncology particularly prostate and bladder cancer. Her research, funded by federal grants and contracts, is

focused on the development of novel therapeutics integrating scientific advances into clinical trials and has contributed to significantly impacting the standards of care for patients with metastatic hormone sensitive and castration resistant prostate cancer.

Her clinical research and scientific leadership led to her roles in leadership of several international clinical trials the data from which led to FDA approvals of Enzalutamide in non metastatic castration resistant prostate cancer, Olaparib in metastatic castration resistant prostate cancer with HRR-m and Darolutamide in metastatic hormone sensitive prostate cancer.

She is also an educator and mentor and have guided the career development of many fellows and young faculty at Wayne State University, the University of Michigan and Northwestern University many of whom have chosen an academic career in GU Oncology.

Prior to joining the Northwestern University faculty Dr. Hussain was a tenured Professor, Departments of Internal Medicine and Urology at the University of Michigan where she served in many scientific and leadership roles at the University of Michigan Comprehensive Cancer Center including Associate Director for Clinical Research and Co-Leader of the Prostate Cancer/Genitourinary Oncology Program, as well as the Associate Chief for Clinical Research in the Division of Hematology/Oncology. Since joining the American Society of Clinical Oncology in 1990, Dr. Hussain has served on numerous committees and boards, including the Scientific Program, Cancer Education, International Affairs, Clinical Practice Guidelines and Cancer Communications committees. In addition, she served as chair of the Cancer Education Committee (2008-2009), the Genitourinary Cancers Symposium Program Committee (2010-2011) and the Genitourinary Cancers Symposium Steering Committee (2013- 2014) and was Associate Editor for Cancer.Net. She was an elected member of the ASCO Board of Directors (2016- 2020).

At the national level Dr. Hussain has served in a variety of scientific leadership roles including the Chair of the SWOG Advanced Prostate

Cancer Subcommittee (1994-2012), member (2009-2014) and Chair (2013- 2014) of the Integration Panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program, and a member (2004-2008) and Chair (2007- 2008) of the U.S. Food and Drug Administration Oncology Drug Advisory Committee. Dr. Hussain has served as a member of the NCI-Cancer Biomarker Study Section and the NCI's Prostate cancer task force. She currently serves as an EAB member for six NCI-designated cancer centers, Meyer Cancer center of Cornell University and the UCLA Prostate Cancer SPORE.

At the international level Dr Hussain serves as a Steering Committee member of MOVEMBER Global Collaborative Program in Disease Progression and a Trustee, Member of Board of Prostate Cancer UK. Dr. Hussain is the author/coauthor of more than 320 scholarly articles and book chapters. She serves/has served on the editorial boards for several national and international specialty journals; She currently serves as the Deputy Editor for Journal of Clinical Investigation.

She has been invited to give hundreds of lectures on her work in the United States and many countries around the world. Dr. Hussain has received many honors and awards, including the University of Michigan Comprehensive Cancer Center Leadership Award (2007), the University of Michigan Medical School League of Research Excellence (2011), and the 2012 Clinical & Health Services Research Award. She was elected as a Fellow of ASCO in 2010. She has been named for many years in America's Top Doctors" and "America's Top Doctors for Cancer and since 2017 she was named Castle Connolly Exceptional Women in Medicine. In 2015 she was named one of OncLive's Giants of Cancer Care.



**Amir Iravani, MD**

Dr. Iravani is a full-time nuclear medicine physician and an Associate Professor of Radiology at the Department of Radiology, University of Washington School of Medicine. He is Theranostics Director at Fred Hutchinson Cancer Center, overseeing or leading multiple theranostic clinical trials. Dr. Iravani has a broad clinical and research interest in molecular imaging and therapeutic nuclear medicine applications in a variety of tumors including neuroendocrine tumors, prostate cancer, and thyroid cancer. His research focuses on molecular imaging and therapeutic nuclear medicine applications in oncology and theranostics. His vision is to improve patient care by using molecular imaging to non-invasively characterize the phenotype of the disease, thereby enabling improved selection of the most appropriate and targeted therapies for patients. Dr. Iravani has contributed to multiple practice-changing clinical trials in prostate cancer including ProPSMA, LuPSMA and TheraP trials as well as several ongoing clinical trials at the University of Washington. He is currently a member of multiple national and international committees in Theranostics including SNMMI and NCI.



**Laurence Klotz, MD, FRCSC**

Dr. Klotz is the former Chief of Urology at Sunnybrook Health Sciences Centre and former President of the Urological Research Society, and the Canadian Urological Association. He is the Founder and Chairman of the Canadian Urology Research Consortium (CURC), and is the Founding Chair of the World Urologic Oncology Federation. He is a Professor of Surgery at the University of Toronto and holds the Sunnybrook Chair of Prostate Cancer Research. Dr. Klotz was the

Founding Editor-in-Chief of both the Canadian Journal of Urology and the Canadian Urology Association Journal, and is now Editor Emeritus of the CUAJ. Dr. Klotz obtained his medical degree from the University of Toronto and completed his residency at the University of Toronto Gallie Program in Surgery. He was a fellow at Memorial Sloan Kettering Cancer Center in New York in uro-oncology. Dr. Klotz is a widely published uro-oncologist with over 550 peer-review publications and 8 books. His main research interest has been prostate cancer. He coined the phrase 'Active Surveillance', and successfully championed this approach for men with favorable risk prostate cancer against substantial resistance. He was the Associate Editor of the Journal of Urology, responsible for Prostate Cancer, for 8 years. Dr. Klotz was awarded the Queen's Jubilee Medal for meritorious public service in 2012, and the University of Toronto Department of Surgery Lister Prize and the Society of Urologic Oncology Medal in 2013. He received the Harold Warwick Award from the Canadian Cancer Society for 'outstanding contributions to cancer control' in 2014. In 2015 he was inducted as a Member of the Order of Canada, Canada's highest civilian award, and received the Richard Williams Award from the AUA in 2016. He received the Dean's Lifetime Achievement Award from the University of Toronto in 2017 and the CUA Lifetime Achievement Award in 2019. He founded the Void, a Canadian all-Urology band, in which he plays keyboard. He is married to Ursula and has two children, Alex, a physics professor at CSULB, and Betsy, a recreational therapist.



**Philip J. Koo, MD**

Dr. Koo is the Chief of Diagnostic Imaging and Physician Executive of Oncology at the Banner MD Anderson Cancer Center in Phoenix, AZ. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr. Koo completed

his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine. Dr. Koo's academic interests have focused on PET imaging in prostate cancer, response to novel therapies using PET, and data-driven image processing.



**Michael Liss, MD, PhD, MAS, MBA, FACS**

Dr. Liss, a urologic oncologist with extensive experience in clinical research, including clinical trials, has a deeply personal connection to prostate cancer. Several of his family members have been diagnosed, which has fueled his dedication to bridging the gap between laboratory discoveries and clinical applications. He earned his Medical Doctor degree with Honors in Research Distinction from the Medical College of Wisconsin and received a National Cancer Institute (NCI) Research Scholar award. His contributions led to two Cancer Proteomics publications as a testament to his commitment to the field. Following medical school, Dr. Liss completed a Urology residency at UC Irvine, where he published research and conducted a groundbreaking clinical trial on prostate biopsy infection prevention. His innovative work led to the development of "Liss Plates," ciprofloxacin agar plates in collaboration with Hardy Diagnostics. Furthering his expertise in urologic oncology, he pursued a fellowship at UCSD and a rigorous two-year Society of Urologic Oncology Fellowship at UC San Diego, earning a Master of Applied Science in Clinical Research with a focus on statistics and clinical trial design. His contributions to microbiology and infection prevention, particularly identifying *E. coli* (ST131) causing post-biopsy infections, resulted in

publications and leadership writing the white paper for the American Urologic Association.

He then completed a Ph.D. in Translational Science at the University of Texas, Austin, in the College of Pharmacy, expanding his work on the microbiome and how it impacts drug metabolism. Further exploring how to utilize microbes in medicine, he also completed his MBA at the University of Texas San Antonio. Dr. Liss states we "cannot let it die in a journal" in that discoveries need to help patients, and the best ones should undergo commercialization.

His dedication to early cancer detection and prevention using an entrepreneurial spirit through novel tools such as imaging and pharmaco-microbiomics underscores his commitment to using innovative solutions to overcome the most pressing challenges in prostate cancer.



**Arturo Mendoza-Valdes, MD**

Dr. Arturo Mendoza-Valdes attended medical school at the National Autonomous University of Mexico (UNAM) in Mexico City. He completed a residency in urology at the Instituto Nacional de Nutrición "Salvador Zubirán" (INNSZ), also in Mexico City. Dr. Mendoza-Valdes has served as a staff member (1987-2000) and Chief of the Urology Department (1988-1996) at the National Cancer Institute of Mexico. He is currently a Professor in the Urology Residency Program at INNSZ.

Dr. Mendoza-Valdes is a former President of the Mexican Urological Association, as well as a former President of the SCS-AUA. In 1998, he and other Mexican urologists founded the Mexican Urologic Oncology Association, where he served as its President 2001-2003 and has served as Scientific Committee Chairman to this day.

Dr. Mendoza-Valdes has organized 29 International Symposiums of Urologic Oncology in Mexico and

25 Annual meetings of the Mexican Urologic Oncology Association. He was a member of the scientific committee of the SIU from 1999 to 2013. He is a Co-Founder of the WUOF (World Urologic Oncology Federation) and has been a member of its steering committee since 2004. He has been a member of the Clinical Practice Guidelines of the AUA (2010-2013), and a member of the Urologic Diagnostic and Therapeutic Imaging Committee (2010 to 2016). Dr. Mendoza-Valdes has also been a member of the SUO (Society of Urologic Oncology) since 2013. In 2012, he became Honorary Member of the EAU, and in 2019 Honorary Member of the AUA. He has participated in 3 ICUD panels on prostate cancer and one on penile cancer. He is currently a member of the IBCG (International Bladder Cancer Group). He is a member of the editorial board of the CJU. Dr. Mendoza-Valdes has served as faculty at IPCU many times



**Martin M. Miner, MD**

Dr. Miner is the founder and former co-director of the Men's Health Center at the Miriam Hospital in Providence, Rhode Island. He served as Chief of Family and Community Medicine for the Miriam Hospital, a teaching hospital of the Warren Alpert School of Medicine from 2008 to 2018. The Men's Health Center under his leadership was the first such center to open in the US. He is the ex-president of the American Society of Men's Health. He is also a clinical professor of family medicine and urology at the Warren Alpert Medical School of Brown University in Providence and has been charged with the development of a multidisciplinary Men's Health Center within the Lifespan/Brown University system since 2008.

Dr. Miner graduated Phi Beta Kappa from Oberlin College with his AB in biology and received his MD from the University of Cincinnati College of Medicine. Upon receiving his MD, he completed his residency at Brown University. He practiced family medicine for 23 years both at

Harvard Pilgrim Health Care and in private practice.

Dr. Miner presently holds memberships in the American Academy of Family Physicians, the RI and Massachusetts Academy of Family Physicians, and American Urologic Association, and is a fellow of the Sexual Medicine Society of North America. He is the President-elect of the Androgen Society developed for the education of providers on the truths of testosterone therapy. Dr. Miner has served on the AUA Guideline Committees for erectile dysfunction, Peyronie's disease, testosterone deficiency and early screening for prostate cancer. He has presented both at the NIH and the White House on men's health initiatives and has authored over 150 peer-reviewed publications and spoken nationally and internationally in multiple venues.

Dr. Miner was chosen the Brown Teacher of the Year in 2003 and 2007 and was recognized by the Massachusetts Medical Society's Award as achieving the most significant contribution to Men's Health: 2012.



**Todd M. Morgan, MD**

Dr. Morgan is the Jack Lapides, M.D. Research Professor and Chief of Urologic Oncology at the University of Michigan, specializing in the evaluation and treatment of genitourinary malignancies. He is also Co-Director of the Weiser Center for Prostate Cancer at the University of Michigan. Dr. Morgan is a translational surgeon-scientist whose research spans preclinical laboratory-based research to prospective clinical trials. His laboratory is focused on developing blood-based tests that can guide precision-based treatments for prostate cancer in real time, and he is principal investigator of two large randomized controlled trials evaluating tissue-based biomarkers in men with localized prostate cancer. Dr. Morgan has been the recipient of Young Investigator Awards from the Prostate Cancer Foundation, Society for Urological Oncology, National Comprehensive Cancer



Network (NCCN), and Society for Basic Urology Research. He has served on a number of national guideline committees, such as the AUA Salvage Therapy for Prostate Cancer Guidelines (Chair), Muscle-Invasive Bladder Cancer Guidelines, the AUA Advanced Prostate Cancer Guidelines, the NCCN Prostate Cancer Guidelines, the ASCO Localized Prostate Cancer Guideline, and the ASCO Molecular Markers for Prostate Cancer Guidelines. His research is supported by multiple sources and includes funding from the Department of Defense, National Cancer Institute, and the Prostate Cancer Foundation.



**Dr. J. Curtis Nickel MD, FRCS**

J. Curtis Nickel is Professor Emeritus, Department of Urology at Queen's University and Kingston Health Sciences Centre in Kingston, Ontario, Canada. Dr. Nickel's research and clinical focus covers inflammatory (including infections), benign prostate (BPH) and pain diseases (prostatitis and interstitial cystitis) of the urinary tract. He is a past president of the Canadian Urological Association (2017), has over 625 publications, has been on the editorial board or editor of 12 Urology journals, presented in over 50 countries, continuously funded by US National Institutes of Health and Canadian Institutes for Health Research (CIHR) for almost his entire career. He has been awarded a CIHR Tier I Canada Research Chair (2007-2022), Society Internationale Urologie Mostafa Elhalili Award (2018) and awards from the American Urological Association including the Distinguished Contribution Award (2009), Latimer Medal (2020), Honorary Lifetime Membership (2021) and the Hugh Hampton Young Award (2023). In 2024 he was given Life Time Achievement Awards from the Society of Benign Prostate Disease and the Canadian Urological Association.



**David S. Morris, MD**

Originally from Cleveland in East Tennessee, Dr. Morris attended The Baylor School in Chattanooga, TN. He graduated Summa Cum Laude from Vanderbilt University and then earned his doctorate from Vanderbilt University School of Medicine. Dr. Morris completed his residency training at The University of Michigan in Ann Arbor, MI with a special research interest in genetics that predict the aggressiveness of prostate and bladder cancers. Since completion of training, he has been with Urology Associates in Nashville, Tennessee. He serves the group as President and the Co-director for the Advanced Therapeutics Center. The ATC center also works closely with the Clinical Research Department as a center for multiple phase 2 and 3 trials primarily focused on GU oncology.



**Peter F. Orio III, DO, MS**

Dr. Peter Orio joined Dana-Farber Brigham Cancer Center (DFBCC) and the faculty at Harvard Medical School on October 1, 2010. Previously, he served in the U.S. Army as the Assistant Chief of Radiation Oncology at Brooke Army Medical Center, where he rose through the ranks to Lieutenant Colonel. He currently serves as the Vice Chair of Network Operations for the DFBCC Department of Radiation Oncology where he shapes and guides the growth of DFBCC to

ensure high-quality care through the standardization of clinical practice, program implementation and staff mentoring. In this role he has played a significant role in the expansion of DFBCC, from two locations and two linear accelerators to four locations and six linear accelerators.

Dr. Orio strives to find innovative solutions for the safe delivery of radioactive isotopes as a cost-effective and efficacious treatment. He continues to expand and direct radiation oncology in the DFBCC network to ensure highly coordinated and integrated care with the main campus facility. This successful model has increased the geographical reach of the DFBCC to patients as we strive to provide the right care, in the right place, at the right time.

Dr. Orio's area of excellence is the clinical expertise and innovation of genitourinary radiation oncology. He continues to explore innovations in the field of brachytherapy and leads a thriving prostate brachytherapy program, which attracts physicians from around the world to observe and learn. He also serves as the Director of Prostate Brachytherapy and has successfully established three prostate brachytherapy programs for DFBCC. These programs utilize advanced treatment planning and radioactive isotope delivery systems providing high quality outcomes with decreased side effects. During his tenure at DFBCC, he has had the opportunity to provide hands-on instruction to radiation oncology residents, urology fellows and attending urology and radiation oncology physicians locally, nationally and internationally.

Dr. Orio remains active in the American Brachytherapy Society (ABS), previously serving as the Chairman of the Membership Committee, where he successfully increased membership every year during his eight-year tenure. He previously served as the Chairman of the Socioeconomics Committee, positioning himself to interact with policy makers to keep the field in the forefront of reimbursement and relevance. In February 2015 Dr. Orio was nationally elected to serve a three-year term on the ABS Board of Directors from June 2018 to June

2019, after which he assumed the role of President, followed by a term as Chairman, and then Past Chairman of the Board. During his time leading the organization he focused his efforts on patient and practitioner education.

He completed the Brigham Leadership Program at Harvard Business School, where he developed an understanding of the key principles that guide healthcare policy in America. Dr. Orio is leveraging this education to interact on the national level in the healthcare reimbursement arena. As the American Society of Therapeutic Radiation Oncology (ASTRO) AMA/RUC Advisor from 2015-2018, he worked to create new treatment codes which were successfully presented to the AMA/ Specialty Society Relative Value Scale Update Committee (RUC) for recommendation to the Centers for Medicare & Medicaid Services (CMS). In 2019 he was elected Vice Chair of the ASTRO Health Policy Committee and in June 2021 he assumed the role of Chair of the Committee, for which he served a two-year term.

Dr. Orio is regularly invited to provide and moderate lectures locally, nationally and internationally on prostate cancer and prostate brachytherapy. He serves on the faculty of both the ABS and ASTRO Annual Meetings, where he provides educational lectures to the membership. Dr. Orio continues to publish on the topic of prostate cancer and prostate brachytherapy in peer reviewed journals. He serves as an ad-hoc reviewer for several journals and is a co-editor for genitourinary malignancies for the "Journal of Contemporary Brachytherapy" and an Associate Editor for the Genitourinary Section of "Brachytherapy."



**William P. Parker, MD**

Dr. Parker is a practicing urologist at The University of Kansas Health System and an associate professor at the University of Kansas Medical Center. He was born in Georgia and received his undergraduate degree at the University of Georgia before attending the Medical College of Georgia. He completed his urology residency at the University of Kansas Medical Center. Prior to joining our faculty, he completed a Society for Urologic Oncology (SUO) fellowship at the Mayo Clinic in Rochester, Minnesota.



**Rut Patel, MD**

Dr. Rut Patel received his medical degree from Rutgers Robert Wood Johnson Medical School in 2013 and then completed his Urologic Surgery residency at Rutgers in 2018. Upon graduation, he joined the University of Southern California Institute of Urology as a Felix and Mildred Yip Fellow in Advanced Robotics/Laparoscopy and Urologic Oncology.

During his time at USC and Rutgers, Dr. Patel has participated in 500+ robotic/laparoscopic procedures using Intuitive Surgical's DaVinci™ Xi and Si platforms. Dr. Patel's experience includes all pathologies of urologic surgery, with a specialization in advanced and cutting-edge robotic techniques: Radical Cystectomy with Intra-corporeal Diversion, Retroperitoneal Access with Robotic Surgery, and complex partial nephrectomies among others.

Dr. Patel has co-authored a number of publications and textbook chapters, as well as presented his research at several regional and national conferences. He has been globally recognized on his work on cost-effectiveness of endoscopic procedures for kidney stones and has won multiple awards for his varied research.




**Daniel P. Petrylak, MD**

Dr. Petrylak was appointed to lead the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, Professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as a Professor of Medicine and began his appointment in September of 2012. Dr. Petrylak is a member of the American Association for Cancer Research, American Society for Clinical Oncology, American College of Physicians, American Association for the Advancement of Science, American Urological Association, and the Southwest Oncology After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee of SWOG. He additionally has led multiple national and international studies in prostate and bladder cancer.

Dr. Petrylak's research interests span both prostate and bladder cancer. He led an investigator initiated trial of docetaxel and estramustine in castration resistant prostate cancer. The results of this study supported a phase 3 trial of this combination in SWOG led by Dr. Petrylak, which in turn, supported the FDA approval of docetaxel for castration resistant prostate cancer. This was one of the first two trials to demonstrate a survival benefit in this state of disease. Dr. Petrylak has also been instrumental in the development of immunotherapy and targeted therapies for refractory bladder cancer. His work with Enfortumab Vedotin has supported the accelerated and full FDA approval of this drug.

Dr. Petrylak received his undergraduate degree from Columbia College and his medical degree from Case Western University School of Medicine. He completed his internship and residency at Albert

Einstein College of Medicine and his fellowship in medical oncology at Memorial SloanKettering Cancer Center. He has authored more than 200 peer-reviewed articles and book chapters on prostate and bladder cancer research outcomes.



**Thomas J. Polascik, MD**

Dr. Thomas J. Polascik is the Lawrence C. Katz Distinguished Professor of Urology and Radiology at the Duke University School of Medicine and a member of the Duke Cancer Institute. He specializes in the treatment of prostate and kidney cancer, with a particular focus on focal therapy, minimally invasive techniques, and robotic surgery. Dr. Polascik earned his medical degree from the University of Chicago Pritzker School of Medicine and completed both his residency and fellowship training at Johns Hopkins University.



**Robert Reiter, MD**

Dr. Reiter is the Bing Professor of Urologic Oncology, Chief of the Division of Urologic Oncology, and Director of UCLA's prostate cancer program. He attended Stanford Medical School, completed his urologic training at Stanford and Baylor College of Medicine, and completed additional fellowship training in urological cancer at the National Cancer Institute. Dr. Reiter was awarded the Outstanding Achievement Award by the Urologic Oncology branch of the National Cancer Institute.

Dr. Reiter is an internationally recognized expert in all areas of prostate cancer management and research. He was among the first to integrate functional MRI imaging and PSMA PET imaging into the diagnosis, surgical management, and care of men with prostate cancer. He was also an early innovator in the field of robotic

surgery, and has completed more than 2,500 robotic prostatectomies.

In addition to surgical management of prostate cancer, Dr. Reiter has expertise in MRI-guided biopsies to diagnose prostate cancer, focal therapy to treat select individuals, as well as all forms of medical therapy. Dr. Reiter has a particular interest in the multidisciplinary management of men with high-risk prostate cancer, incorporating the latest in genomics, clinical trials, and precision medical therapies into treatment plans in collaboration with UCLA leaders in the areas of radiation, medical and nuclear prostate oncology.

In addition to his broad clinical interests in prostate cancer, Dr. Reiter is a leading researcher in prostate cancer and has led UCLA's 12 million SPORE grant, which supports work to translate laboratory discoveries into clinical advances, for more than 15 years. Drugs such as enzalutamide and apalutamide, and imaging tools such as PSMA PET, are among the many advances that have emanated from this program. His own laboratory discovered the prostate stem cell antigen and developed antibodies to target this protein, which has led to novel imaging and therapeutic approaches for prostate cancer currently in clinical trials. Dr. Reiter has authored more than 250 papers and lectures nationally and internationally on all aspects of clinical care of men with prostate cancer.



**Scott Sellinger, MD**

Dr. Sellinger has been a partner at Southeastern Urological Center, now a division of Advanced Urology Institute, since 1991. He received his B.S. degree in Chemistry from Syracuse University, and attended Medical School at the University of Florida in Gainesville. He completed his Urology residency at the University of Florida and has lived in Tallahassee for over 30 years. He was President of the Capital Medical Society in 2003, and served as President of the Florida Urological Society in 2005.



In 2018, he served as President of the Southeastern Section of the American Urological Association (SESAUA). In 2019, he served as President of the American Association of Clinical Urologists (AACU). In addition to his urology specific work, Dr. Sellinger has developed a special interest in risk management and prevention of medical errors and has lectured extensively on this subject matter. He is also interested in large group practice development and management.

For several years, Dr. Sellinger has served on the board of Advanced Urology Institute (AUI) representing his care center in Tallahassee. In January 2021, he became the second President of AUI, now one of the largest independent urology practices in the United States. Dr. Sellinger currently chairs the Advanced Prostate Cancer (APC)

Committee and oversees seven APC clinics within AUI. Since 2015, has also served on the Large Urology Group Practice Association (LUGPA) Board of Directors, where he currently serves as Secretary. At LUGPA, he is proud to represent over 2300 Urologists by working to preserve and advance the independent practice of urology.



**Paul Sieber, MD**

Dr. Sieber is the Medical Director for Clinical Trials at Keystone Urology. He went to Purdue University and obtained his undergraduate degree in Biology before receiving his medical degree from Indiana University. He did his residency in general surgery and urology at the M.S. Hershey Medical Center, Penn State University. He has been involved with clinical trials for 20 years having worked on more than 200 studies. The bulk of these have focused on prostate cancer. Dr. Sieber is very enthusiastic about clinical trials and research as he looks at what can benefit his patients in the future. Many of today's state-of-the-art treatments for prostate cancer have

been investigated right here in Lancaster including Xgeva, Zytiga, Xtandi, Erleada, and Firmagon. Numerous diagnostic tests including OncotypeDX, Prolaris, Decipher, and 4K score have also been studied here. Furthermore, Keystone Urology has been a long-term participant in CAPSURE, an observational database with more than 150 publications. Dr. Sieber has authored numerous peer-reviewed articles and presented many posters at meetings including the AUA, ASCO, ASCO GU, SUO, and SIU.



**LUGPA**  
Integrated Practices  
Comprehensive Care

LUGPA 2025 GLOBAL PROSTATE CANCER CONGRESS

# THANK YOU TO OUR SPONSORS

## THANK YOU

to our LUGPA 2025  
Global Prostate Cancer  
Congress Exhibitors

### Gold Partners

---

**Astellas Oncology & Pfizer Oncology**  
**AstraZeneca**  
**Johnson & Johnson**  
**Novartis Pharmaceuticals Corporation**  
**Tolmar**

### Silver Partners

---

**Bayer**  
**Lantheus**

### Bronze Partners

---

**Merck & Co., Inc.**


### Exhibitors

---

**Artera**  
**Cencora**  
**Clarity Pharmaceuticals**  
**Cleveland Diagnostics**  
**Doc Lab Inc.**  
**EmeritusDX/Freedom**  
**Pathology Partners**  
**Exosome Diagnostics**  
**GoPath Diagnostics**  
**Myriad Genetics**

**Pfizer Oncology**  
**Privado Health**  
**Sun Pharma**  
**Teleflex**  
**Telix Pharmaceuticals**  
**Theragenics**  
**URO-1, Inc.**  
**Vision RT**

# FLOOR PLAN



**INDUSTRY PARTNER**

Artera	3
Astellas Oncology & Pfizer Oncology	2
AstraZeneca	14
Bayer	19
Cencora	10
Clarity Pharmaceuticals	11
Cleveland Diagnostics	4
Doc Lab Inc.	22
EmeritusDX/ Freedom Pathology Partners	24
Exosome Diagnostics	16
GoPath Diagnostics	7
Johnson & Johnson	6
Lantheus	25

**TABLE #**

**INDUSTRY PARTNER**

Merck & Co., Inc.	15
Myriad Genetics	12
Novartis Pharmaceuticals Corporation	21
Pfizer Oncology	1
Privado Health	23
Sun Pharma	20
Teleflex	8
Telix Pharmaceuticals	5
Theragenics	13
Tolmar	9
URO-1, Inc.	17
Vision RT	18

**TABLE #**



# 2025 LUGPA EVENTS

**The Urology Resident Summit  
and Job Fair**

**Feb. 28-March 1, 2025**  
JW Marriott Orlando  
Bonnet Creek Resort & Spa  
Orlando, FL

**Houston Regional Meeting**

**March 14-15, 2025**  
JW Marriott  
Houston by the Galleria  
Houston, TX

**Prostate Cancer Academy**

**March 20-22, 2025**  
Westin Irving Convention Center  
Dallas, TX

**Ambulatory Surgery  
Center Academy**

**May 29-31, 2025**  
Scottsdale Resort & Spa  
Scottsdale, AZ

**Boston Regional Meeting**

**June 20-21, 2025**  
The Westin Copley Place  
Boston, MA


**Bladder & Kidney  
Cancer Academy**

**October 16-18, 2025**  
The Hilton BNA Nashville  
Airport, 2 Terminal Dr  
Nashville, TN

**LUGPA 2025  
Annual Meeting**

**November 6-8, 2025**  
Marriott Magnificent  
Mile Hotel  
Chicago, IL

# Third Edition of LUGPA's Guidebook



**NOW AVAILABLE**

LUGPA members can download a PDF for free. Hardcopies are available for purchase here: [bit.ly/LUGPAGuidebook](http://bit.ly/LUGPAGuidebook).



**Practice Management for Urology Groups** LUGPA's Guidebook was created to provide today's urology group practices with a reference manual that provides the basics of group practice management and explores more advanced topics that serve as a catalyst for groups to advance patient care by adopting an integrated approach to care delivery.

**New chapters** cover rapid access clinics, new service lines, private equity investments, burnout, artificial intelligence and DEI. This book is a must-read for all group practice leaders – physicians and administrators alike.

In LUGPA's Guidebook, you'll learn:

- Essential tips for managing your practice
- How to form and merge group practices
- Group governance and operations
- Physician compensation methods and alternatives
- Key considerations in private equity deals
- Negotiations with hospitals for service line agreements
- How to establish a comprehensive bladder cancer clinic, and more!

**"This book draws upon the collective wisdom of seasoned urologists, healthcare administrators, and industry experts."**

Evan R. Goldfischer, MD, MBA, MPH

Thanks to our sponsors for their support of this publication:

